US5916891A
(en)
|
1992-01-13 |
1999-06-29 |
Smithkline Beecham Corporation |
Pyrimidinyl imidazoles
|
US6524832B1
(en)
|
1994-02-04 |
2003-02-25 |
Arch Development Corporation |
DNA damaging agents in combination with tyrosine kinase inhibitors
|
US6046208A
(en)
*
|
1996-01-11 |
2000-04-04 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
WO1998007425A1
(en)
|
1996-08-21 |
1998-02-26 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
JP2002504909A
(ja)
|
1997-06-13 |
2002-02-12 |
スミスクライン・ビーチャム・コーポレイション |
新規な置換ピラゾールおよびピラゾリン化合物
|
EP0994870A4
(en)
|
1997-06-19 |
2002-10-23 |
Smithkline Beecham |
NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
|
US6562832B1
(en)
|
1997-07-02 |
2003-05-13 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
WO1999001452A1
(en)
|
1997-07-02 |
1999-01-14 |
Smithkline Beecham Corporation |
Novel cycloalkyl substituted imidazoles
|
US6362193B1
(en)
|
1997-10-08 |
2002-03-26 |
Smithkline Beecham Corporation |
Cycloalkenyl substituted compounds
|
WO1999032121A1
(en)
|
1997-12-19 |
1999-07-01 |
Smithkline Beecham Corporation |
Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
|
ATE229017T1
(de)
*
|
1998-02-02 |
2002-12-15 |
Lg Chemical Ltd |
Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
|
TR200003472T2
(tr)
|
1998-05-22 |
2001-09-21 |
Smithkline Beecham Corporation |
Yeni 2-alkil ikameli imidazol bileşikler
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
GB9812523D0
(en)
*
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
FR2780892B1
(fr)
*
|
1998-07-08 |
2001-08-17 |
Sod Conseils Rech Applic |
Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
|
WO2000016778A1
(en)
*
|
1998-09-24 |
2000-03-30 |
Merck & Co., Inc. |
A method of treating cancer
|
AU1909200A
(en)
|
1998-11-04 |
2000-05-22 |
Smithkline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
AU3247700A
(en)
*
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6316462B1
(en)
*
|
1999-04-09 |
2001-11-13 |
Schering Corporation |
Methods of inducing cancer cell death and tumor regression
|
US7122666B2
(en)
|
1999-07-21 |
2006-10-17 |
Sankyo Company, Limited |
Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
|
AU1623601A
(en)
|
1999-11-22 |
2001-06-04 |
Smithkline Beecham Plc |
Novel compounds
|
ATE305787T1
(de)
|
1999-11-23 |
2005-10-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
|
DE60020595T2
(de)
|
1999-11-23 |
2006-03-16 |
Smithkline Beecham Corp. |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
US6759410B1
(en)
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
CA2423154A1
(en)
|
2000-09-21 |
2002-03-28 |
David Kenneth Dean |
Imidazole derivatives as raf kinase inhibitors
|
WO2002026246A2
(en)
*
|
2000-09-29 |
2002-04-04 |
Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh |
Pharmaceutical compositions comprising polynucleotides encoding a raf protein
|
MXPA03003011A
(es)
|
2000-10-05 |
2003-07-14 |
George Q Daley |
Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
|
GB0121488D0
(en)
|
2001-09-05 |
2001-10-24 |
Smithkline Beecham Plc |
Compounds
|
EP1432699A1
(en)
*
|
2001-09-05 |
2004-06-30 |
Smithkline Beecham Plc |
Pyridylfurans and pyrroles as raf kinase inhibitors
|
US7307071B2
(en)
*
|
2001-12-04 |
2007-12-11 |
Onyx Pharmaceuticals, Inc |
RAF-MEK-ERK pathway inhibitors to treat cancer
|
WO2004004725A2
(en)
|
2002-07-09 |
2004-01-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
US6878731B2
(en)
*
|
2002-08-14 |
2005-04-12 |
Pure World Botanicals, Inc. |
Imidazole alkaloids from Lepidium meyenii and methods of usage
|
CN101899006B
(zh)
|
2002-08-19 |
2013-11-06 |
劳洛斯治疗公司 |
2,4,5-三取代的咪唑及其作为抗菌剂的用途
|
DE60334016D1
(de)
|
2002-11-05 |
2010-10-14 |
Glaxo Group Ltd |
Antibakterielle mittel
|
MXPA05012377A
(es)
|
2003-05-15 |
2006-05-25 |
Arqule Inc |
Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
|
JP2007507540A
(ja)
*
|
2003-10-02 |
2007-03-29 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤としての化合物および組成物
|
US8969372B2
(en)
|
2003-11-14 |
2015-03-03 |
Aptose Boisciences Inc. |
Aryl imidazoles and their use as anti-cancer agents
|
US7829560B2
(en)
|
2004-07-08 |
2010-11-09 |
Arqule, Inc. |
1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
JP2008517064A
(ja)
|
2004-10-19 |
2008-05-22 |
アークル インコーポレイテッド |
P38mapキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
AU2006250809B2
(en)
|
2005-05-25 |
2011-05-12 |
Lorus Therapeutics Inc. |
2-indolyl imidazo(4,5-D)phenanthroline derivatives and their use in the treatment of cancer
|
TWI468162B
(zh)
|
2005-12-13 |
2015-01-11 |
英塞特公司 |
作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶
|
UY30639A1
(es)
*
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
SG10201509887UA
(en)
|
2007-06-13 |
2016-01-28 |
Incyte Corp |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
HUE030800T2
(en)
|
2008-10-07 |
2017-05-29 |
Astrazeneca Uk Ltd |
Pharmaceutical Form No. 514
|
SG176111A1
(en)
|
2009-05-22 |
2011-12-29 |
Incyte Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
EA025520B1
(ru)
|
2009-05-22 |
2017-01-30 |
Инсайт Холдингс Корпорейшн |
N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
|
WO2011028685A1
(en)
|
2009-09-01 |
2011-03-10 |
Incyte Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
MX347851B
(es)
|
2010-03-10 |
2017-05-16 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
WO2012068450A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
CA2839767A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
BR112015010663B1
(pt)
|
2012-11-15 |
2022-12-06 |
Incyte Holdings Corporation |
Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
|
CN105189509B
(zh)
|
2013-03-06 |
2017-12-19 |
因赛特公司 |
用于制备jak抑制剂的方法及中间体
|
CA2903866A1
(en)
|
2013-03-20 |
2014-09-25 |
Aptose Biosciences Inc. |
2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
|
RS60469B1
(sr)
|
2013-08-07 |
2020-07-31 |
Incyte Corp |
Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
|
US20150104392A1
(en)
|
2013-10-04 |
2015-04-16 |
Aptose Biosciences Inc. |
Compositions, biomarkers and their use in the treatment of cancer
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
CA3081261A1
(en)
|
2017-10-30 |
2019-05-09 |
Aptose Biosciences Inc. |
Aryl imidazoles for the treatment of cancer
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
WO2019152374A1
(en)
|
2018-01-30 |
2019-08-08 |
Incyte Corporation |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
MX2022012285A
(es)
|
2018-03-30 |
2023-08-15 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022249192A1
(en)
*
|
2021-05-27 |
2022-12-01 |
Ramot At Tel-Aviv University Ltd. |
Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors
|